{"id":14282,"date":"2023-09-04T23:33:00","date_gmt":"2023-09-04T15:33:00","guid":{"rendered":"https:\/\/flcube.com\/?p=14282"},"modified":"2024-11-22T23:38:02","modified_gmt":"2024-11-22T15:38:02","slug":"amgen-and-horizon-therapeutics-reach-agreement-with-ftc-to-proceed-with-acquisition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14282","title":{"rendered":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition"},"content":{"rendered":"\n<p>Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency&#8217;s legal challenges to Amgen&#8217;s acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed by the FTC earlier this year, which expressed concerns that Amgen could use rebates from its blockbuster products to influence insurers and intermediaries to favor Horizon\u2019s high-cost drugs, Tepezza (teprotumumab) and Krystexxa (pegloticase). These drugs are the sole treatments available for thyroid eye disease and chronic refractory gout, respectively.<\/p>\n\n\n\n<p><strong>Amgen&#8217;s Commitment to Fair Competition<\/strong><br>Amgen has restated its original response, asserting that it has no plans to bundle Tepezza or Krystexxa with any of its products. This commitment is crucial in addressing the FTC&#8217;s concerns about potential anti-competitive practices in the market.<\/p>\n\n\n\n<p><strong>Path to Acquisition Clearance and Expected Timeline<\/strong><br>The consent order agreement with the FTC clears the way for the acquisition to proceed, pending approval by the authorities of Horizon\u2019s Irish homeland. The companies expect this final approval to be concluded during the fourth quarter of 2023, allowing the acquisition to be completed within the anticipated timeframe.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,61],"tags":[330,2278,912,2279,24],"class_list":["post-14282","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-legal-ip","tag-amgen","tag-horizon-therapeutics","tag-nasdaq-amgn","tag-nasdaq-hznp","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency&#039;s legal challenges to Amgen&#039;s acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed by the FTC earlier this year, which expressed concerns that Amgen could use rebates from its blockbuster products to influence insurers and intermediaries to favor Horizon\u2019s high-cost drugs, Tepezza (teprotumumab) and Krystexxa (pegloticase). These drugs are the sole treatments available for thyroid eye disease and chronic refractory gout, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14282\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14282\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-04T15:33:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-22T15:38:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition\",\"datePublished\":\"2023-09-04T15:33:00+00:00\",\"dateModified\":\"2024-11-22T15:38:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amgen\",\"Horizon Therapeutics\",\"NASDAQ: AMGN\",\"NASDAQ: HZNP\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14282#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14282\",\"name\":\"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-09-04T15:33:00+00:00\",\"dateModified\":\"2024-11-22T15:38:02+00:00\",\"description\":\"Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency's legal challenges to Amgen's acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed by the FTC earlier this year, which expressed concerns that Amgen could use rebates from its blockbuster products to influence insurers and intermediaries to favor Horizon\u2019s high-cost drugs, Tepezza (teprotumumab) and Krystexxa (pegloticase). These drugs are the sole treatments available for thyroid eye disease and chronic refractory gout, respectively.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14282\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14282#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition - Insight, China&#039;s Pharmaceutical Industry","description":"Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency's legal challenges to Amgen's acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed by the FTC earlier this year, which expressed concerns that Amgen could use rebates from its blockbuster products to influence insurers and intermediaries to favor Horizon\u2019s high-cost drugs, Tepezza (teprotumumab) and Krystexxa (pegloticase). These drugs are the sole treatments available for thyroid eye disease and chronic refractory gout, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14282","og_locale":"en_US","og_type":"article","og_title":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14282","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-09-04T15:33:00+00:00","article_modified_time":"2024-11-22T15:38:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14282#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14282"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition","datePublished":"2023-09-04T15:33:00+00:00","dateModified":"2024-11-22T15:38:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14282"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amgen","Horizon Therapeutics","NASDAQ: AMGN","NASDAQ: HZNP","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14282#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14282","url":"https:\/\/flcube.com\/?p=14282","name":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-09-04T15:33:00+00:00","dateModified":"2024-11-22T15:38:02+00:00","description":"Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with the US Federal Trade Commission (FTC), which they anticipate will resolve the antitrust agency's legal challenges to Amgen's acquisition of Horizon. The conflict arose from a preliminary injunction motion and temporary restraining order (TRO) filed by the FTC earlier this year, which expressed concerns that Amgen could use rebates from its blockbuster products to influence insurers and intermediaries to favor Horizon\u2019s high-cost drugs, Tepezza (teprotumumab) and Krystexxa (pegloticase). These drugs are the sole treatments available for thyroid eye disease and chronic refractory gout, respectively.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14282#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14282"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14282#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14282"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14282\/revisions"}],"predecessor-version":[{"id":14284,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14282\/revisions\/14284"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}